GSK Set To File Votrient For Ovarian Cancer On Strong PFS
This article was originally published in The Pink Sheet Daily
Votrient demonstrated a 5.6 month PFS improvement compared to placebo in a Phase III ovarian cancer study presented at the ASCO annual meeting, but no overall survival benefit yet. Nevertheless, GSK believes that the risk/benefit profile is good enough now to support filings in the U.S. and Europe.
You may also be interested in...
Genentech Likely To Wait For Survival Data For U.S. Filing Of Avastin In Ovarian Cancer
Avastin proves progression-free survival benefit for tough-to-treat patients in AURELIA, the drug’s fourth positive Phase III ovarian cancer study. Genentech says it plans to “engage” with FDA regarding a filing, but acknowledges that the agency may want more data, possibly showing an overall survival benefit.
FDA Opts For Full, Rather Than Accelerated, Approval Of GSK’s Votrient In Sarcoma
Despite advisory committee discussion about a possible accelerated approval for pazopanib with a confirmatory study to assess symptom benefit, the agency opted to grant regular approval, as had been requested by GlaxoSmithKline.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.